Scleroderma nursing: assessment, interventions, and NCLEX review

Scleroderma (systemic sclerosis, SSc) is a chronic autoimmune connective tissue disease defined by three overlapping processes: vascular injury, immune activation, and progressive fibrosis. The result is abnormal collagen deposition in the skin and internal organs — lungs, kidneys, heart, and gastrointestinal tract — that can be life-limiting. It affects women four to five times more often than men, with peak onset between ages 30 and 50. For nursing students, scleroderma is high-yield because it combines complex multi-organ pathophysiology with clear-cut NCLEX safety priorities — most notably the corticosteroid-renal crisis rule that many review resources underemphasize.

Quick reference: scleroderma at a glance

Pathophysiology: why scleroderma causes fibrosis

Three mechanisms drive scleroderma’s pathology, and they are closely intertwined. First, vascular injury to small arterioles and capillaries triggers endothelial cell activation — the endothelium releases endothelin-1 (a potent vasoconstrictor) and reactive oxygen species, setting off progressive vascular remodeling. This obliterates small vessels and explains why Raynaud’s phenomenon is typically the first symptom.

Second, activated fibroblasts differentiate into myofibroblasts, which synthesize and deposit far more collagen than normal. This fibrosis cascade progressively stiffens skin, lungs, kidneys, and myocardium. Third, T-cell and B-cell dysregulation sustains the inflammatory drive — B cells produce autoantibodies (ANA, anti-Scl-70, anti-centromere) that serve as both disease markers and contributors to end-organ damage.

Genetic susceptibility amplifies all three mechanisms. First-degree relatives of people with SSc carry a 13-fold higher prevalence. Environmental triggers — silica dust, organic solvents, vinyl chloride — can unmask disease in susceptible individuals.

Classification: limited vs diffuse systemic sclerosis

The distinction between limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) guides prognosis, monitoring intensity, and treatment focus.

Limited cutaneous SSc (lcSSc) confines skin thickening to the hands, forearms, and face — distal to the elbows and knees. Patients typically have a long prodrome of Raynaud’s phenomenon (sometimes years or decades) before skin changes emerge. The classic clinical syndrome within lcSSc is CREST syndrome:

• C — Calcinosis cutis (calcium deposits in soft tissue)
• R — Raynaud’s phenomenon
• E — Esophageal dysmotility (lower esophageal sphincter hypotonia → GERD, dysphagia)
• S — Sclerodactyly (skin tightening and hardening of fingers)
• T — Telangiectasia (dilated superficial blood vessels, especially on face and hands)

Pulmonary arterial hypertension (PAH) is the primary cause of death in lcSSc, often appearing years into the disease when lung vasculature has undergone progressive obliteration.

Diffuse cutaneous SSc (dcSSc) involves skin proximal to the elbows, the trunk, and the face, and it progresses rapidly. Interstitial lung disease (ILD) and scleroderma renal crisis (SRC) are the dominant life-threatening complications in dcSSc, and both tend to occur early in the disease course — often within the first three to five years.

Raynaud’s phenomenon

Raynaud’s phenomenon (RP) occurs in more than 95% of SSc patients and is typically the first symptom by months or years. It represents vasospasm of digital arteries and arterioles triggered by cold exposure or emotional stress, producing a characteristic triphasic color change:

1. White (pallor) — vasospasm causes blood to leave the digits; the fingers turn white and numb
2. Blue (cyanosis) — deoxygenated blood pools in the digit; fingers turn blue-purple with paresthesia
3. Red (erythema) — vasospasm resolves; blood rushes back; digits turn red and may be painful

In SSc, Raynaud’s frequently progresses beyond vasospasm to structural vascular damage — digital ulcerations affect approximately 50% of SSc patients over their lifetime, and advanced ischemia can result in digital gangrene requiring amputation.

Nailfold capillaroscopy — examination of capillary loops at the nail base with an ophthalmoscope or dedicated capillaroscope — is abnormal in more than 95% of SSc patients. Giant capillaries, avascular areas, and architectural disorganization are highly specific for SSc-pattern Raynaud’s and help distinguish secondary Raynaud’s (in SSc) from primary Raynaud’s (benign, no structural disease).

Nursing management of Raynaud’s

• Teach the patient to keep hands, feet, and core warm — layering gloves, socks, and hats before going outside
• Avoid cold triggers: refrigerated items, air conditioning, cold water
• Teach emotional stress management (vasospasm responds to sympathetic activation)
• Calcium channel blockers (nifedipine is first-line) reduce frequency and severity of attacks
• Phosphodiesterase-5 inhibitors (sildenafil) are used for moderate-to-severe Raynaud’s and digital ulcer prevention
• Inspect digits regularly for ulceration, infection, or ischemic changes — early identification prevents progression
• Educate patients to never apply direct heat (heating pads) to ischemic fingers — burns can occur due to impaired sensation

Skin manifestations

Skin involvement in SSc is bilateral, symmetric, and begins distally. Key manifestations nurses assess for:

Sclerodactyly is the tightening and hardening of the skin over the fingers and hands. The skin appears tense and shiny — patients lose the ability to make a fist, and finger flexion contractures can develop. The Mahler’s fist test (inability to make a complete fist) is a useful bedside assessment. Sclerodactyly restricts activities of daily living and increases fall risk when hand contractures impair grip.

Calcinosis cutis refers to calcium phosphate deposits in subcutaneous tissue, most common over fingertips, elbows, and pressure points. Deposits can ulcerate through the skin and become infected. Nursing priorities include wound care, infection monitoring, and pain management.

Telangiectasias are dilated blood vessel mats visible on the face, lips, hands, and mucous membranes. They are not dangerous in isolation but are markers of disease burden.

Salt-and-pepper dyspigmentation — areas of hyperpigmentation interspersed with hypopigmentation — occurs on the trunk and extremities and reflects uneven melanin deposition in fibrotic skin.

Hidebound skin describes the overall tethering of skin to underlying structures, reducing tissue mobility. On the face, this produces an expressionless, “masked” appearance — thinning of the lips, reduction of oral aperture (microstomia), and prominence of perioral wrinkles. Reduced mouth opening (measured by inter-incisor distance) can complicate dental care, eating, and airway management.

Gastrointestinal involvement

GI dysmotility is the most common non-skin manifestation of SSc, affecting up to 90% of patients across all segments of the GI tract.

Esophageal dysmotility is the most frequent GI manifestation and a defining feature of CREST syndrome. Fibrosis of the lower esophageal sphincter (LES) causes hypotonia — the LES fails to maintain barrier function, resulting in chronic GERD. Patients describe heartburn, regurgitation, and dysphagia. Management follows standard GERD protocols (see GERD nursing for pharmacologic and positioning interventions), but SSc patients are at higher risk for severe complications: erosive esophagitis, Barrett’s esophagus, and peptic strictures. Head-of-bed elevation to 30–45° and avoidance of eating within three hours of lying down are essential patient education points.

Gastric involvement can produce gastroparesis (delayed gastric emptying), causing early satiety, bloating, nausea, and vomiting. Prokinetics (metoclopramide) may be prescribed. A rare but characteristic finding is gastric antral vascular ectasia (GAVE, “watermelon stomach”), which can cause occult GI bleeding and iron deficiency anemia.

Small bowel involvement leads to bacterial overgrowth from impaired peristalsis. Colonized organisms ferment nutrients, producing bloating, diarrhea, malabsorption, and deficiencies in folate, vitamin B12, and fat-soluble vitamins. Weight loss and protein-calorie malnutrition are common late findings. Rotating antibiotics (metronidazole, ciprofloxacin, rifaximin) are used for bacterial overgrowth.

Anorectal involvement causes fecal incontinence and rectal prolapse in some patients — a source of significant distress and social isolation.

GI nursing priorities

• Assess nutritional status at every visit — weight trend, albumin, signs of deficiency
• Position head of bed elevated; avoid supine positioning after meals
• Encourage small, frequent meals; avoid foods that relax the LES (caffeine, alcohol, fatty foods, chocolate)
• Monitor for occult bleeding (stool guaiac, hemoglobin trend)
• Provide dysphagia precautions if significant esophageal disease is documented
• Refer to dietitian for patients with malabsorption or significant weight loss

Pulmonary involvement

Pulmonary disease is the leading cause of mortality in SSc. Two distinct complications affect the lungs, each with different pathophysiology, monitoring approach, and treatment:

Interstitial lung disease

ILD occurs in up to 90% of SSc patients on high-resolution CT imaging, though clinically significant ILD affects roughly 40–50%. It is more prevalent and more severe in dcSSc, particularly in patients with anti-Scl-70 antibodies. The pathology is predominantly non-specific interstitial pneumonia (NSIP) — ground-glass opacification on HRCT progressing to honeycombing and traction bronchiectasis in severe cases.

Pulmonary function tests show a restrictive pattern: reduced forced vital capacity (FVC), reduced total lung capacity (TLC), and reduced diffusing capacity for carbon monoxide (DLCO) — the last being the most sensitive early indicator. An ILD extent greater than 20% of the lung parenchyma on HRCT correlates with poorer survival.

Auscultation reveals bilateral basal inspiratory crackles. Dry cough and progressive dyspnea on exertion are the predominant symptoms. See pleural effusion nursing for a broader review of pleural and pulmonary nursing assessment principles.

Treatment: Nintedanib (a tyrosine kinase inhibitor) is approved for SSc-ILD and has demonstrated slowing of FVC decline. Mycophenolate mofetil is widely used as a first-line immunosuppressive. Tocilizumab has emerging evidence. Cyclophosphamide is reserved for severe or progressive ILD given its toxicity profile.

Pulmonary arterial hypertension

PAH complicates 10–15% of SSc patients and carries a five-year survival rate of roughly 50–70% without treatment. It is more prevalent in lcSSc and CREST syndrome. The mechanism is progressive obliteration of the pulmonary microvasculature — the same vascular injury driving Raynaud’s, affecting the lung circulation.

Clinically, patients develop progressive dyspnea on exertion, fatigue, syncope, and eventually right heart failure (peripheral edema, elevated JVP, hepatomegaly). For a full review of right heart failure assessment and management, see heart failure nursing.

Key diagnostics:

• Echocardiography: estimated right ventricular systolic pressure (RVSP) >40 mmHg suggests PAH
• Right heart catheterization is the gold standard — confirms mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest
• 6-minute walk test (6MWT) assesses functional capacity and tracks response to treatment
• BNP/NT-proBNP elevation indicates right ventricular strain

See pulmonary hypertension nursing for full PAH management details.

Treatment: PAH-targeted therapies include:

• Endothelin receptor antagonists (bosentan, ambrisentan)
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil)
• Prostanoids (epoprostenol IV — the most potent, reserved for WHO functional class III–IV)
• Soluble guanylate cyclase stimulators (riociguat)

Nursing priorities for PAH include monitoring for right heart failure signs, avoiding fluid overload, managing supplemental oxygen, and patient safety counseling (avoid pregnancy — PAH in pregnancy carries very high maternal mortality).

Scleroderma renal crisis

Scleroderma renal crisis (SRC) is a potentially fatal complication defined by the abrupt onset of severe hypertension and rapidly progressive acute kidney injury. It occurs in 10–15% of SSc patients, predominantly in those with dcSSc and anti-RNA polymerase III antibodies, and typically strikes within the first four years of disease.

The underlying mechanism is obliterative vasculopathy of the renal vasculature, causing the kidney to perceive persistent ischemia and activate the renin-angiotensin-aldosterone system (RAAS) — which drives malignant hypertension, further renal ischemia, and a self-amplifying cycle.

Clinical presentation:

• Abrupt elevation of blood pressure — often systolic >150–180 mmHg in a patient who was previously normotensive
• Oliguria or anuria (acute kidney injury)
• Microangiopathic hemolytic anemia (MAHA) — fragmented red cells on peripheral smear (schistocytes)
• Thrombocytopenia (from platelet consumption in damaged small vessels)
• Headache, visual changes, or hypertensive encephalopathy in severe cases

Without treatment, SRC was the leading cause of death in SSc before the ACE inhibitor era.

Treatment — ACE inhibitors are the treatment of choice. Captopril is the preferred agent due to its short half-life and established evidence base. ACE inhibition reverses the RAAS activation that drives malignant hypertension in SRC. Patients may require dialysis support during the acute phase but can recover renal function over weeks to months with adequate BP control — even after starting hemodialysis, continued ACE inhibitor therapy should not be stopped. See CKD/ESRD nursing for renal replacement therapy principles.

Critical safety point — corticosteroids: Corticosteroids at doses greater than 10 mg prednisone equivalent per day are strongly associated with precipitating scleroderma renal crisis, particularly in patients with dcSSc. This is a major NCLEX safety point. If a patient with SSc is prescribed high-dose corticosteroids for another indication, alert the prescriber — alternative immunosuppression should be considered. When steroids cannot be avoided, use the lowest effective dose and monitor renal function and blood pressure closely.

Cardiac involvement

Cardiac disease in SSc is common but frequently subclinical — only 15–25% of patients develop symptomatic cardiac complications, but when they do, prognosis is poor (estimated two-year mortality of ~60% in symptomatic primary cardiac SSc).

Myocardial fibrosis replaces normal myocardium with collagen, causing diastolic dysfunction and, in severe cases, systolic dysfunction and heart failure. Patchy fibrosis follows a microvascular injury pattern — it is not confined to coronary artery territories, which distinguishes it from ischemic cardiomyopathy.

Pericarditis and pericardial effusion are common incidental findings on echocardiography. Most effusions are small and hemodynamically insignificant, but large effusions causing tamponade can occur.

Conduction abnormalities — first-degree AV block, bundle branch blocks, and arrhythmias — result from fibrosis of the conduction system. Ventricular arrhythmias are a recognized cause of sudden cardiac death in SSc. Holter monitoring is used for arrhythmia surveillance in symptomatic patients.

Diagnostics

Antibody testing

ANA is positive in more than 95% of SSc patients, making it a sensitive but non-specific screening tool. Disease-specific antibodies carry both diagnostic and prognostic significance:

Imaging and functional testing

• HRCT chest — gold standard for ILD detection; ground-glass opacification, reticular shadowing, honeycombing
• Pulmonary function tests (PFTs) — FVC and DLCO measured at baseline and annually; DLCO reduction precedes symptoms
• Echocardiography — screens for PAH (estimated RVSP), pericardial effusion, and ventricular function; performed annually
• Right heart catheterization — gold standard for PAH confirmation when echocardiography suggests elevated pressures
• Nailfold capillaroscopy — identifies SSc-pattern capillary changes; highly useful in early undifferentiated disease
• Esophageal manometry — confirms LES hypotonia and esophageal dysmotility
• 6-minute walk test — functional assessment for PAH monitoring
• Renal function panel + urinalysis — creatinine, BUN, urine protein:creatinine ratio; monitor every three to six months in dcSSc
• Hand X-ray — identifies calcinosis, joint space narrowing, and acro-osteolysis (resorption of distal phalanges)

Pharmacologic management by organ system

No medication cures SSc or reverses established fibrosis, but organ-targeted therapy significantly reduces morbidity and mortality.

Raynaud’s phenomenon:

• First-line: dihydropyridine calcium channel blockers (nifedipine extended-release)
• Second-line: phosphodiesterase-5 inhibitors (sildenafil, tadalafil) — especially for digital ulcers
• Digital ulcers: intravenous iloprost (prostanoid) for severe or non-healing ulcers
• Endothelin receptor antagonists (bosentan) reduce digital ulcer recurrence

Interstitial lung disease:

• Nintedanib (Ofev) — anti-fibrotic; FDA approved for SSc-ILD; monitor hepatotoxicity (LFTs), GI side effects
• Mycophenolate mofetil — immunosuppressive; first-line at many centers; monitor CBC for cytopenias
• Cyclophosphamide — reserved for severe ILD; significant toxicity (hemorrhagic cystitis, gonadal toxicity, malignancy)
• Tocilizumab (anti-IL-6) — evidence of slowing lung function decline in early dcSSc

Pulmonary arterial hypertension:

• Endothelin receptor antagonists: bosentan, ambrisentan — teratogenic; monthly pregnancy tests required; monitor LFTs
• PDE-5 inhibitors: sildenafil, tadalafil — vasodilatory; avoid concomitant nitrates
• Prostanoids: epoprostenol (continuous IV infusion via central line) — most potent; high infection risk; pump failure is life-threatening
• Riociguat (soluble guanylate cyclase stimulator) — cannot be combined with PDE-5 inhibitors

Scleroderma renal crisis:

• ACE inhibitors — captopril preferred; titrate rapidly to control blood pressure
• Target BP: reduce mean arterial pressure by no more than 25% in the first 24 hours to avoid watershed ischemia
• Continue ACE inhibitor even if dialysis is required

Skin thickening and immunosuppression:

• Methotrexate — evidence for reducing skin score in early dcSSc
• Mycophenolate mofetil — broadly used for skin and pulmonary manifestations
• Cyclophosphamide — severe skin disease or ILD

Organ involvement and nursing interventions

Scleroderma vs SLE vs RA: NCLEX differentiation

NCLEX frequently asks students to differentiate between autoimmune diseases. The table below highlights the key distinguishing features of scleroderma, SLE, and RA. For an in-depth review of SLE nursing and rheumatoid arthritis nursing, see the linked references.

Nursing priorities summary

Skin integrity and comfort

Scleroderma skin is fragile, poorly perfused, and slow to heal. Inspect at every encounter — particularly fingertips, bony prominences, and calcinosis sites. Moisturize with thick emollients to combat xerosis. Handle skin gently during any procedure. Teach patients that calcinosis deposits can break through the skin and require immediate wound care attention.

Thermoregulation and Raynaud’s management

Raynaud’s is not just an inconvenience — in SSc, digital ulcers can progress to gangrene. Patient education on layering strategies, trigger avoidance, and early reporting of new ulcers is a primary nursing responsibility. Medication adherence to vasodilators (CCBs, PDE-5 inhibitors) must be reinforced at every visit.

Nutrition and swallowing safety

Esophageal dysmotility, gastroparesis, and malabsorption create significant nutritional risk. Maintain aspiration precautions (30–45° HOB after meals), educate on small frequent meals, and monitor weight and albumin trends. Any dysphagia complaint warrants formal swallowing evaluation.

Pain management

Pain in SSc is multifactorial: ischemic pain from Raynaud’s, calcinosis tenderness, joint and tendon pain, esophageal spasm, and neuropathic pain from digital nerve damage. A multimodal approach is appropriate — pharmacologic (analgesics, vasodilators, gastroprotectives) alongside non-pharmacologic strategies.

Fall prevention

Sclerodactyly and hand contractures impair grip strength and fine motor function, increasing fall risk significantly. Document grip strength and functional limitations. Arrange OT assessment for adaptive equipment (jar openers, button hooks, modified utensils). Ensure the environment is free from trip hazards.

Psychosocial support

SSc creates profound body image disruption — facial changes, visible telangiectasias, cold-sensitive hands that patients feel they must hide. Raynaud’s can limit the ability to work in cold environments. Dysphagia and GI symptoms cause social difficulty around eating. Screen systematically for depression and anxiety (PHQ-9, GAD-7), and connect patients with SSc-specific support organizations (Scleroderma Foundation).

Medication safety education

Patients must understand the corticosteroid restriction — over-the-counter steroid courses, injections, or prescriptions from other providers must be flagged and communicated to the rheumatologist before use. Educate patients to tell every healthcare provider they see about their SSc diagnosis.

NCLEX tips for scleroderma

1. Scleroderma renal crisis is triggered by high-dose corticosteroids — greater than 10 mg/day prednisone equivalent in a patient with diffuse SSc is a high-risk situation. If an NCLEX question describes a patient with scleroderma who was recently started on prednisone 40 mg and now has acute hypertension and oliguria, the answer is scleroderma renal crisis.

2. ACE inhibitors — specifically captopril — are the treatment of choice for SRC. This is a reversal of the usual renal failure logic (where ACE inhibitors are often avoided in AKI). In SRC, the mechanism is RAAS overactivation, so ACE inhibitors are lifesaving.

3. Anti-centromere antibody = limited SSc / CREST. Anti-Scl-70 = diffuse SSc with ILD risk. Anti-RNA polymerase III = diffuse SSc with renal crisis risk.

4. The CREST mnemonic identifies the five hallmarks of limited SSc: Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, Telangiectasia.

5. Raynaud’s triphasic color change goes: white → blue → red. White = vasospasm (pallor); blue = deoxygenation (cyanosis); red = reperfusion (erythema and pain). Cold and stress are triggers.

6. Right heart catheterization is the gold standard for PAH diagnosis — not echocardiography. Echo estimates RVSP but cannot confirm the diagnosis. Mean PAP ≥25 mmHg at rest on right heart cath is definitive.

7. PFTs in SSc-ILD show a restrictive pattern — decreased FVC, TLC, and DLCO. DLCO is the most sensitive early indicator of both ILD and PAH.

8. Never apply direct heat to ischemic fingers in Raynaud’s — impaired sensation increases burn risk. Gradual warming with gloves and environmental temperature change is the correct approach.

9. Esophageal dysmotility management includes elevating the head of bed 30–45°, small frequent meals, and proton pump inhibitors. This is an NCLEX favorite because it combines a disease-specific complication with a general nursing intervention.

10. Nailfold capillaroscopy distinguishes primary Raynaud’s (normal capillaries) from secondary Raynaud’s in SSc (giant capillaries, avascular areas). It is non-invasive and performed with an ophthalmoscope or capillaroscope.

11. Bosentan (endothelin receptor antagonist) used for PAH and digital ulcer prevention is teratogenic — monthly pregnancy tests and two methods of contraception are required for women of childbearing age.

12. Epoprostenol infusion must never be interrupted. Even a brief interruption of this continuous IV prostanoid can cause life-threatening rebound pulmonary vasoconstriction. Nurses managing patients on epoprostenol must have backup supply, trained patient/family caregivers at home, and clear emergency protocols.

References: StatPearls — Scleroderma (Odonwodo et al., 2023); ACR — Guidelines for Management of Systemic Sclerosis; American College of Rheumatology Scleroderma Classification Criteria; EULAR recommendations for SSc management. This reference page is for educational purposes and does not constitute medical advice.